Shares of Intervacc AB jumped 20% to €0.06 on November 3 after the Swedish animal-health company released real-world data showing its horse vaccine against strangles — a highly contagious bacterial disease — achieved what it called "close to 100 percent protection." The company announced that data from the use of the vaccine points to close to 100 percent protection. For a micro-cap burning cash every quarter, the question is whether stellar field data can translate into revenue fast enough to justify the rally.
Three Infections Out of 100,000 Doses Is a Powerful Marketing Number. Intervacc reported real-world data showing nearly 100% protection, announced November 3, 2026. Out of approximately 100,000 doses sold across the EU and UK, only three confirmed infections were found among fully vaccinated horses — an incidence rate of just 0.006%. In clinical challenge studies the vaccine demonstrated 94% protection, and 100% in many field studies. Moving from controlled trials to mass-market proof removes a key adoption barrier for skeptical veterinarians and horse owners.
European Sales Are Growing, but the Base Is Tiny. Strangvac sales surged 300% in Europe , and Swedish revenue rose 54% in the first half of 2026 . Yet the company posted an operating loss of roughly SEK 42.8 million for the first half , against annual trailing revenue of only about $2 million. Q1 net sales came in at just SEK 3.4 million while the operating loss widened to SEK 22.2 million. Impressive percentage growth on a small base still leaves the company deeply unprofitable.
The U.S. Is the Real Prize — and It's Still Years Away. The U.S. market has approximately 10 million horses and remains a top priority.
Safety studies in the U.S. began in December 2025, and efficacy studies are planned for the second half of 2026.
A U.S. launch is targeted for 2028. That timeline means at least two more years of heavy cash consumption before accessing a market roughly 50% larger than Europe.
Q3 Earnings on November 12 Will Test the Rally. The Q3 2026 earnings release is scheduled for November 12. Investors will scrutinize dose-volume trends and cash runway. Analysts carry a consensus target price of SEK 2.00 — more than double the current level — but that target hinges on successful U.S. entry and scaling European demand. The real-world data strengthens the product story; whether it accelerates adoption fast enough to outrun the burn rate is the open bet.